J&J Snaps Up Rare Cell Capture And Analysis Technology From Mass General
Executive SummaryMass General has signed a $30 million deal with two units of J&J to develop a new system for capturing and analyzing circulating tumor cells (CTCs). The collaboration aims to develop a standardized diagnostic platform for biomarker analysis of DNA, RNA, or protein from tumor cells collected noninvasively. J&J will take the indications for its current CTC system, CellSearch, and migrate them to the new platform.
You may also be interested in...
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.